Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial-Reference-Cited by-同舟云学术

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial

Published:2018-04-23 Issue:6 Volume:103 Page:2291-2301
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Rodbard Helena W¹,Lingvay Ildiko²,Reed John³,de la Rosa Raymond⁴,Rose Ludger⁵,Sugimoto Danny⁶,Araki Eiichi⁷,Chu Pei-Ling⁸,Wijayasinghe Nelun⁹,Norwood Paul¹⁰

Affiliation:

1. Endocrine and Metabolic Consultants, Rockville, Maryland

2. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas

3. Endocrine Research Solutions, Inc., Roswell, Georgia

4. Four Rivers Clinical Research, Paducah, Kentucky

5. Institute of Diabetes Research, Münster, Germany

6. Cedar-Crosse Research Center, Chicago, Illinois

7. Department of Metabolic Medicine, Kumamoto University, Kumamoto, Japan

8. Novo Nordisk Inc., Plainsboro, New Jersey

9. Novo Nordisk A/S, Søborg, Denmark

10. University of California at San Francisco, Fresno, California

Publisher

The Endocrine Society

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/article-pdf/103/6/2291/25088249/jc.2018-00070.pdf

Reference40 articles.

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33);UK Prospective Diabetes Study (UKPDS) Group;Lancet,1998

2. Patient adherence to medication requirements for therapy of type 2 diabetes;Bailey;Int J Clin Pract,2011

3. 10-year follow-up of intensive glucose control in type 2 diabetes;Holman;N Engl J Med,2008

4. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study;Ohkubo;Diabetes Res Clin Pract,1995

5. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study;Stratton;BMJ,2000

Cited by 255 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Semaglutide for the management of diabesity: The real-world experience;World Journal of Methodology;2024-09-20

2. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial;The Lancet Diabetes & Endocrinology;2024-09

3. Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide;Endocrine Practice;2024-09

4. The effectiveness of 0.5 mg and 1mg of semaglutide in patients with type two diabetes and predictors of response: a retrospective cohort study;Frontiers in Endocrinology;2024-08-14

5. Real‐world safety profile of once‐weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real‐world Evidence (SURE) programme;Diabetes, Obesity and Metabolism;2024-08-08